Presentation and complications associated with cirrhosis of the liver

References

• Murphy SL, Xu J, Kochanek KD; Division of Vital Statistics. Deaths: final data for 2010. Natl Vital Stat Rep 2013;61:1-117
   PubMedGoogle Scholar
• Asrani SK, Larson JJ, Yawn B, et al. Underestimation of liver-related mortality in the United States. Gastroenterology 2013;145:375-82
   PubMed Web of Science ®Google Scholar
• US Burden of Disease Collaborators. The state of US health, 1990-2010: burden of diseases, injuries, and risk factors. JAMA 2013;310:591-608
   PubMed Web of Science ®Google Scholar
• García-Pagán JC, Gracia-Sancho J, Bosch J. Functional aspects on the pathophysiology of portal hypertension in cirrhosis. J Hepatol 2012;57:458-61
   PubMed Web of Science ®Google Scholar
• Starr SP, Raines D. Cirrhosis: diagnosis, management, and prevention. Am Fam Physician 2011;84:1353-9
   PubMed Web of Science ®Google Scholar
• Zipprich A, Garcia-Tsao G, Rogowski S, et al. Prognostic indicators of survival in patients with compensated and decompensated cirrhosis. Liver Int 2012;32:1407-14
   PubMed Web of Science ®Google Scholar
• Ginés P, Quintero E, Arroyo V, et al. Compensated cirrhosis: natural history and prognostic factors. Hepatology 1987;7:122-8
   PubMed Web of Science ®Google Scholar
• Malhi H, Guicciardi ME, Gores GJ. Hepatocyte death: a clear and present danger. Physiol Rev 2010;90:1165-94
   PubMed Web of Science ®Google Scholar
• Hall JE. General principles of gastrointestinal function—motility, nervous control, and blood circulation. In: Hall JE, editor. Guyton and hall textbook of medical physiology. 12th ed. Philadelphia, PA: Saunders, 2011:753-62
   Google Scholar
• Bolognesi M, Di Pascoli M, Verardo A, et al. Splanchnic vasodilation and hyperdynamic circulatory syndrome in cirrhosis. World J Gastroenterol 2014;20:2555-63
   PubMed Web of Science ®Google Scholar
• Liou IW. Management of end-stage liver disease. Med Clin North Am 2014;98:119-52
   PubMed Web of Science ®Google Scholar
• Poca M, Puente A, Graupera I, et al. Prognostic markers in patients with cirrhosis and portal hypertension who have not bled. Dis Markers 2011;31:147-54
   PubMed Web of Science ®Google Scholar
• Berzigotti A, Seijo S, Reverter E, et al. Assessing portal hypertension in liver diseases. Expert Rev Gastroenterol Hepatol 2013;7:141-55
   PubMed Web of Science ®Google Scholar
• Garcia-Tsao G, Sanyal AJ, Grace ND, et al; Practice Guidelines Committee of the American Association for the Study of Liver Diseases; Practice Parameters Committee of the American College of Gastroenterology. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology 2007;46:922-38
   PubMed Web of Science ®Google Scholar
• Pinzone MR, Celesia BM, Di Rosa M, et al. Microbial translocation in chronic liver diseases. Int J Microbiol 2012;2012:694629
   PubMedGoogle Scholar
• Garcia-Tsao G, Lim JK, Members of the Veterans Affairs Hepatitis C Resource Center Program. Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program. Am J Gastroenterol 2009;104:1802-29
   PubMed Web of Science ®Google Scholar
• Mueller S, Seitz HK, Rausch V. Non-invasive diagnosis of alcoholic liver disease. World J Gastroenterol 2014;20:14626-41
   PubMed Web of Science ®Google Scholar
• Kohlhaas A, Durango E, Millonig G, et al. Transient elastography with the XL probe rapidly identifies patients with nonhepatic ascites. Hepat Med 2012;4:11-18
   Google Scholar
• Pugh RN, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646-9
   PubMed Web of Science ®Google Scholar
• Rigsbee L, Agans R, Shankar V, et al. Quantitative profiling of gut microbiota of children with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2012;107:1740-51
   PubMed Web of Science ®Google Scholar
• Kamath PS, Kim WR. The model for end-stage liver disease (MELD). Hepatology 2007;45:797-805
   PubMed Web of Science ®Google Scholar
• Jaurigue MM, Cappell MS. Therapy for alcoholic liver disease. World J Gastroenterol 2014;20:2143-58
   PubMed Web of Science ®Google Scholar
• Toshikuni N, Arisawa T, Tsutsumi M. Hepatitis C-related liver cirrhosis - strategies for the prevention of hepatic decompensation, hepatocarcinogenesis, and mortality. World J Gastroenterol 2014;20:2876-87
   PubMed Web of Science ®Google Scholar
• Schwenger KJ, Allard JP. Clinical approaches to non-alcoholic fatty liver disease. World J Gastroenterol 2014;20:1712-23
   PubMed Web of Science ®Google Scholar
• Heidelbaugh JJ, Bruderly M. Cirrhosis and chronic liver failure: part I. Diagnosis and evaluation. Am Fam Physician 2006;74:756-62
   PubMed Web of Science ®Google Scholar
• Mellinger JL, Volk ML. Multidisciplinary management of patients with cirrhosis: a need for care coordination. Clin Gastroenterol Hepatol 2013;11:217-23
   PubMed Web of Science ®Google Scholar
• D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006;44:217-31
   PubMed Web of Science ®Google Scholar
• Garcia-Tsao G, Groszmann RJ, Fisher RL, et al. Portal pressure, presence of gastroesophageal varices and variceal bleeding. Hepatology 1985;5:419-24
   PubMed Web of Science ®Google Scholar
• O'Brien J, Triantos C, Burroughs AK. Management of varices in patients with cirrhosis. Nat Rev Gastroenterol Hepatol 2013;10:402-12
   PubMed Web of Science ®Google Scholar
• D'Amico G, Garcia-Pagan JC, Luca A, et al. Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis: a systematic review. Gastroenterology 2006;131:1611-24
   PubMed Web of Science ®Google Scholar
• Cesario KB, Choure A, Modha K, et al. Variceal hemorrhage. Cleveland, OH: Cleveland Clinic Foundation, 2014. Available at: http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/hepatology/variceal-hemorrhage/. Accessed April 16, 2014
   Google Scholar
• Gluud LL, Krag A. Banding ligation versus beta-blockers for primary prevention in oesophageal varices in adults. Cochrane Database Syst Rev 2012;8:CD004544:1-68
   Google Scholar
• Li L, Yu C, Li Y. Endoscopic band ligation versus pharmacological therapy for variceal bleeding in cirrhosis: a meta-analysis. Can J Gastroenterol 2011;25:147-55
   PubMed Web of Science ®Google Scholar
• Loffroy R, Estivalet L, Cherblanc V, et al. Transjugular intrahepatic portosystemic shunt for the management of acute variceal hemorrhage. World J Gastroenterol 2013;19:6131-43
   PubMed Web of Science ®Google Scholar
• García-Pagán JC, Caca K, Bureau C, et al. Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med 2010;362:2370-9
   PubMed Web of Science ®Google Scholar
• Gordon FD. Ascites. Clin Liver Dis 2012;16:285-99
   PubMed Web of Science ®Google Scholar
• Hsu SJ, Huang HC. Management of ascites in patients with liver cirrhosis: recent evidence and controversies. J Chin Med Assoc 2013;76:123-30
   PubMed Web of Science ®Google Scholar
• Perri GA. Ascites in patients with cirrhosis. Can Fam Physician 2013;59:1297-9
   PubMed Web of Science ®Google Scholar
• Moore KP, Aithal GP. Guidelines on the management of ascites in cirrhosis. Gut 2006;55(Suppl 6):vi1-12
   PubMedGoogle Scholar
• Runyon BA. Management of adult patients with ascites due to cirrhosis: update 2012. Alexandria, VA: American Association for the Study of Liver Diseases, 2013. Available at: http://www.guideline.gov/content.aspx?id=45103. Accessed May 20, 2014
   Google Scholar
• Moore CM, Van Thiel DH. Cirrhotic ascites review: pathophysiology, diagnosis and management. World J Hepatol 2013;5:251-63
   PubMedGoogle Scholar
• Angeli P, Dalla Pria M, De Bei E, et al. Randomized clinical study of the efficacy of amiloride and potassium canrenoate in nonazotemic cirrhotic patients with ascites. Hepatology 1994;19:72-9
   PubMed Web of Science ®Google Scholar
• Saab S, Nieto JM, Lewis SK, et al. TIPS versus paracentesis for cirrhotic patients with refractory ascites. Cochrane Database Syst Rev 2006;18:CD004889
   Google Scholar
• Chen RP, Zhu Ge XJ, Huang ZM, et al. Prophylactic use of transjugular intrahepatic portosystemic shunt aids in the treatment of refractory ascites: metaregression and trial sequential meta-analysis. J Clin Gastroenterol 2014;48:290-9
   PubMed Web of Science ®Google Scholar
• Bellot P, Welker MW, Soriano G, et al. Automated low flow pump system for the treatment of refractory ascites: a multi-center safety and efficacy study. J Hepatol 2013;58:922-7
   PubMed Web of Science ®Google Scholar
• Koulaouzidis A, Bhat S, Karagiannidis A, et al. Spontaneous bacterial peritonitis. Postgrad Med J 2007;83:379-83
   PubMed Web of Science ®Google Scholar
• Morencos FC, de las Heras Castaño G, Martín Ramos L, et al. Small bowel bacterial overgrowth in patients with alcoholic cirrhosis. Dig Dis Sci 1995;40:1252-6
   PubMed Web of Science ®Google Scholar
• Singal AK, Salameh H, Kamath PS. Prevalence and in-hospital mortality trends of infections among patients with cirrhosis: a nationwide study of hospitalised patients in the United States. Aliment Pharmacol Ther 2014;40:105-12
   PubMed Web of Science ®Google Scholar
• Sort P, Navasa M, Arroyo V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999;341:403-9
   PubMed Web of Science ®Google Scholar
• Sigal SH, Stanca CM, Fernandez J, et al. Restricted use of albumin for spontaneous bacterial peritonitis. Gut 2007;56:597-9
   PubMed Web of Science ®Google Scholar
• Hanouneh MA, Hanouneh IA, Hashash JG, et al. The role of rifaximin in the primary prophylaxis of spontaneous bacterial peritonitis in patients with liver cirrhosis. J Clin Gastroenterol 2012;46:709-15
   PubMed Web of Science ®Google Scholar
• Vlachogiannakos J, Viazis N, Vasianopoulou P, et al. Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis. J Gastroenterol Hepatol 2013;28:450-5
   PubMed Web of Science ®Google Scholar
• Kalambokis GN, Mouzaki A, Rodi M, et al. Rifaximin for the prevention of spontaneous bacterial peritonitis. World J Gastroenterol 2012;18:1700-2
   PubMed Web of Science ®Google Scholar
• Nair S, Verma S, Thuluvath PJ. Pretransplant renal function predicts survival in patients undergoing orthotopic liver transplantation. Hepatology 2002;35:1179-85
   PubMed Web of Science ®Google Scholar
• Lata J. Hepatorenal syndrome. World J Gastroenterol 2012;18:4978-84
   PubMed Web of Science ®Google Scholar
• Ginès P, Schrier RW. Renal failure in cirrhosis. N Engl J Med 2009;361:1279-90
   PubMed Web of Science ®Google Scholar
• Licata A, Maida M, Bonaccorso A, et al. Clinical course and prognostic factors of hepatorenal syndrome: a retrospective single-center cohort study. World J Hepatol 2013;5:685-91
   PubMedGoogle Scholar
• Ginès P, Guevara M, Arroyo V, et al. Hepatorenal syndrome. Lancet 2003;362:1819-27
   PubMed Web of Science ®Google Scholar
• Skagen C, Einstein M, Lucey MR, et al. Combination treatment with octreotide, midodrine, and albumin improves survival in patients with type 1 and type 2 hepatorenal syndrome. J Clin Gastroenterol 2009;43:680-5
   PubMed Web of Science ®Google Scholar
• Solà E, Cárdenas A, Ginès P. Results of pretransplant treatment of hepatorenal syndrome with terlipressin. Curr Opin Organ Transplant 2013;18:265-70
   PubMed Web of Science ®Google Scholar
• Gluud LL, Christensen K, Christensen E, et al. Terlipressin for hepatorenal syndrome. Cochrane Database Syst Rev 2012;9:CD005162
   PubMed Web of Science ®Google Scholar
• Safdar Z, Bartolome S, Sussman N. Portopulmonary hypertension: an update. Liver Transpl 2012;18:881-91
   PubMed Web of Science ®Google Scholar
• Krowka MJ, Miller DP, Barst RJ, et al. Portopulmonary hypertension: a report from the US-based REVEAL Registry. Chest 2012;141:906-15
   PubMed Web of Science ®Google Scholar
• Mancuso L, Scordato F, Pieri M, et al. Management of portopulmonary hypertension: new perspectives. World J Gastroenterol 2013;19:8252-7
   PubMed Web of Science ®Google Scholar
• Swanson KL, Wiesner RH, Nyberg SL, et al. Survival in portopulmonary hypertension: Mayo Clinic experience categorized by treatment subgroups. Am J Transplant 2008;8:2445-53
   PubMed Web of Science ®Google Scholar
• Bismuth M, Funakoshi N, Cadranel JF, et al. Hepatic encephalopathy: from pathophysiology to therapeutic management. Eur J Gastroenterol Hepatol 2011;23:8-22
   PubMed Web of Science ®Google Scholar
• Rose C, Kresse W, Kettenmann H. Acute insult of ammonia leads to calcium-dependent glutamate release from cultured astrocytes, an effect of pH. J Biol Chem 2005;280:20937-44
   PubMed Web of Science ®Google Scholar
• Shawcross D, Jalan R. The pathophysiologic basis of hepatic encephalopathy: central role for ammonia and inflammation. Cell Mol Life Sci 2005;62:2295-304
   PubMed Web of Science ®Google Scholar
• Häussinger D, Schliess F. Pathogenetic mechanisms of hepatic encephalopathy. Gut 2008;57:1156-65
   PubMed Web of Science ®Google Scholar
• Said A, Williams J, Holden J, et al. Model for end stage liver disease score predicts mortality across a broad spectrum of liver disease. J Hepatol 2004;40:897-903
   PubMed Web of Science ®Google Scholar
• Stepanova M, Mishra A, Venkatesan C, et al. In-hospital mortality and economic burden associated with hepatic encephalopathy in the United States from 2005 to 2009. Clin Gastroenterol Hepatol 2012;10:1034-41
   PubMed Web of Science ®Google Scholar
• Khungar V, Poordad F. Hepatic encephalopathy. Clin Liver Dis 2012;16:301-20
   PubMed Web of Science ®Google Scholar
• Prakash RK, Kanna S, Mullen KD. Evolving concepts: the negative effect of minimal hepatic encephalopathy and role for prophylaxis in patients with cirrhosis. Clin Ther 2013;35:1458-73
   PubMed Web of Science ®Google Scholar
• Koziarska D, Wunsch E, Milkiewicz M, et al. Mini-mental state examination in patients with hepatic encephalopathy and liver cirrhosis: a prospective, quantified electroencephalography study. BMC Gastroenterol 2013;13:107
   PubMed Web of Science ®Google Scholar
• Bajaj JS, Saeian K, Schubert CM, et al. Minimal hepatic encephalopathy is associated with motor vehicle crashes: the reality beyond the driving test. Hepatology 2009;50:1175-83
   PubMed Web of Science ®Google Scholar
• Román E, Córdoba J, Torrens M, et al. Minimal hepatic encephalopathy is associated with falls. Am J Gastroenterol 2011;106:476-82
   PubMed Web of Science ®Google Scholar
• Gupta A, Dhiman RK, Kumari S, et al. Role of small intestinal bacterial overgrowth and delayed gastrointestinal transit time in cirrhotic patients with minimal hepatic encephalopathy. J Hepatol 2010;53:849-55
   PubMed Web of Science ®Google Scholar
• Neff G. Pharmacoeconomics of hepatic encephalopathy. Pharmacotherapy 2010;30:28S-32S
   PubMed Web of Science ®Google Scholar
• Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med 2010;362:1071-81
   PubMed Web of Science ®Google Scholar
• Vilstrup H, Amodio P, Bajaj J, et al. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology 2014;60:715-35
   PubMed Web of Science ®Google Scholar
• Mullen KD, Ferenci P, Bass NM, et al. An algorithm for the management of hepatic encephalopathy. Semin Liver Dis 2007;27:32-48
   Web of Science ®Google Scholar
• Blei AT, Córdoba J; Practice Parameters Committee of the American College of Gastroenterology. Hepatic encephalopathy. Am J Gastroenterol 2001;96:1968-76
   PubMed Web of Science ®Google Scholar
• Prakash R, Mullen KD. Mechanisms, diagnosis and management of hepatic encephalopathy. Nat Rev Gastroenterol Hepatol 2010;7:515-25
   PubMed Web of Science ®Google Scholar
• Mullen KD, Sanyal AJ, Bass NM, et al. Rifaximin is safe and well tolerated for long-term maintenance of remission from overt hepatic encephalopathy. Clin Gastroenterol Hepatol 2014;12:1390-7
   PubMed Web of Science ®Google Scholar
• Kimer N, Krag A, Møller S, et al. Systematic review with meta-analysis: the effects of rifaximin in hepatic encephalopathy. Aliment Pharmacol Ther 2014;40:123-32
   PubMed Web of Science ®Google Scholar
• Agrawal A, Sharma BC, Sharma P, et al. Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open-label, randomized controlled trial of lactulose, probiotics, and no therapy. Am J Gastroenterol 2012;107:1043-50
   PubMed Web of Science ®Google Scholar
• Sharma BC, Sharma P, Agrawal A, et al. Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo. Gastroenterology 2009;137:885-91
   PubMed Web of Science ®Google Scholar
• Neff G. Factors affecting compliance and persistence with treatment for hepatic encephalopathy. Pharmacotherapy 2010;30:22S-7S
   Google Scholar
• Bajaj JS, Saeian K, Christensen KM, et al. Probiotic yogurt for the treatment of minimal hepatic encephalopathy. Am J Gastroenterol 2008;103:1707-15
   PubMed Web of Science ®Google Scholar
• Sharma P, Sharma BC, Puri V, et al. An open-label randomized controlled trial of lactulose and probiotics in the treatment of minimal hepatic encephalopathy. Eur J Gastroenterol Hepatol 2008;20:506-11
   PubMed Web of Science ®Google Scholar
• Bajaj JS, Heuman DM, Wade JB, et al. Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy. Gastroenterology 2011;140:478-87
   PubMed Web of Science ®Google Scholar
• Cohen-Naftaly M, Friedman SL. Current status of novel antifibrotic therapies in patients with chronic liver disease. Therap Adv Gastroenterol 2011;4:391-417
   PubMedGoogle Scholar
• Schuppan D, Kim YO. Evolving therapies for liver fibrosis. J Clin Invest 2013;123:1887-901
   PubMed Web of Science ®Google Scholar
• Gagnon L, Geerts L, Doucet A, et al. Oral treatment with PBI-4050, a novel first-in-class anti-fibrotic compound, reduces hepatic fibrosis and hepatocellular carcinoma. Presented at: 2014 Annual Meeting of the European Association for the Study of the Liver; April 9-13, 2014; London, United Kingdom
   Google Scholar
• Lefebvre E, Hashiguchi T, Jenkins H, et al. Anti-fibrotic and anti-inflammatory activity of the dual CCR2 and CCR5 antagonist cenicriviroc in a mouse model of NASH. Hepatology 2013;58(Suppl 1):221A-2A
   Google Scholar
• Abramovitch S, Sharvit E, Weisman Y, et al. Vitamin D inhibits development of liver fibrosis in animal model but cannot ameliorate established cirrhosis. Hepatology 2013;58(Suppl 1):590A
   Google Scholar
• Oyarzun JE, Tiebosch M, Quintero P, et al. Coffee and liver disease: evidence of beneficial effects in experimental non-alcoholic steatohepatitis and of direct antifibrotic properties of caffeine in vitro. Hepatology 2013;58(Suppl 1):502A
   Google Scholar
• Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol 2008;64:1147-61
   PubMed Web of Science ®Google Scholar
• de Kanter CT, Drenth JP, Arends JE, et al. Viral hepatitis C therapy: pharmacokinetic and pharmacodynamic considerations. Clin Pharmacokinet 2014;53:409-27
   PubMed Web of Science ®Google Scholar
• Afdhal N, Everson G, Calleja JL, et al. Sofosbuvir and ribavirin for the treatment of chronic HCV with cirrhosis and portal hypertension with and without decompensation: early virologic response and safety. J Hepatology 2014;60:S28
   Web of Science ®Google Scholar
• Marzano A, Marengo A, Marietti M, et al. Lactic acidosis during Entecavir treatment in decompensated hepatitis B virus-related cirrhosis. Dig Liver Dis 2011;43:1027-8
   PubMedGoogle Scholar
• Cichoz-Lach H, Celinski K, Slomka M, et al. Pathophysiology of portal hypertension. J Physiol Pharmacol 2008;59(Suppl 2):231-8
   PubMedGoogle Scholar
• Roderburg C, Luedde T. The role of the gut microbiome in the development and progression of liver cirrhosis and hepatocellular carcinoma. Gut Microbes 2014;5:441-5
   PubMed Web of Science ®Google Scholar
• Giannelli V, Di Greggorio V, Iebba V, et al. Microbiota and the gut-liver axis: bacterial translocation, inflammation and infection in cirrhosis. World J Gastroenterol 2014;20:16795-810
   PubMed Web of Science ®Google Scholar